Symptoms and General Pathology

All Conditions

Nervous System Diseases

Heart and Blood Diseases

Death

Plaque, Atherosclerotic

Disease Progression

Constriction, Pathologic

Carotid Stenosis

Pathological Conditions, Anatomical

Carotid Artery Diseases

Cerebrovascular Disorders

Brain Diseases

Central Nervous System Diseases

Arterial Occlusive Diseases

Vascular Diseases

Antineoplastic Agents

All Drugs and Chemicals

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months

PD-1 immune checkpoint blockades

Jianan Wang, MD, PhD

Lin Fan, PhD

A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

This is a perspective, self-controlled cohort study. This study aims to evaluate the effectiveness of anti-PD-1 mAbs (PD-1 immune checkpoint blockades) on atherosclerotic carotid plaques in those anti-PD-1 mAbs treated patients. The method for quantification and evaluation of atherosclerotic plaques are based on the: ① The mean intima-media thickness of the common carotid artery (Mean CCA thickness); ② The maximum intima-media thickness of the internal carotid artery (maximum ICA thickness); ③ Carotid plaque burden: by calculation of the plaque area of atherosclerotic plaques on the long axis direction of artery on the ultrasound images. By comparing the above-mentioned parameters at the same location of carotid artery in each patient when initiate the first-dose of anti-PD-1 mAbs therapy and 3 months post anti-PD-1 mAbs therapy. It is designed to assess the effectiveness of anti-PD-1 mAbs on the progression of carotid plaques.

It was measured over a segment of the common carotid artery that was 1 cm long, located approximately 0.5 cm below the carotid-artery bulb, and considered not to contain any plaque (i.e., not to have any perceivable protrusion of the artery wall into the lumen).

It was defined as the greatest intima-media thickness in either the right or left internal carotid artery extending from the bulb to 1 cm above the carotid sinus, ascertained from a total of four views on each side.

Carotid plaque area measured by ultrasound (cross-sectional area of longitudinal views of all plaques seen) to quantify the increase or decrease of atherosclerotic carotid plaques.

Second Affiliated Hospital, School of Medicine, Zhejiang University

dosage form: intravenous injection; frequency: 2-3 weeks; duration: at least 3 months

PD-1 inhibitor

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

This is a self-control, multi-center observational study. This study aims to evaluate the effectiveness of anti-PD-1 mAbs on atherosclerotic plaques in those anti-PD-1 mAbs treated patients. The method for quantification and evaluation of atherosclerotic plaques are based on the calculation of the plaque area of atherosclerotic plaques on the long axis direction of artery on the ultrasound images. By comparing the plaque areas at the same location of artery in each patient before and after anti-PD-1 mAbs treatments, to assess the progression of atherosclerotic plaques response to anti-PD-1 mAbs.

Comparison of the sizes of plaque areas at the same locations on artery ultrasound before and after anti-PD-1 mAbs treatments.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up	NCT05123287	Plaque, Atheros... Immune Checkpoi... Programmed Cell... Carotid Artery ... Intimal Medial ...	PD-1 immune che...	18 Years - 90 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up	NCT04922541	Plaque, Atheros... Programmed Cell...	PD-1 inhibitor	18 Years - 90 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University

Spots Global Cancer Trial Database for plaque, atherosclerotic